Omeros (OMER) Expected to Announce Earnings on Thursday

Omeros (NASDAQ:OMER) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $0.40 million for the quarter.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter in the prior year, the firm earned ($0.15) earnings per share. On average, analysts expect Omeros to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Omeros Trading Up 16.6%

Shares of OMER opened at $4.43 on Wednesday. Omeros has a 12 month low of $3.00 and a 12 month high of $13.60. The firm’s 50 day moving average is $7.28 and its 200-day moving average is $8.15. The stock has a market capitalization of $258.30 million, a PE ratio of -1.92 and a beta of 2.42.

Analyst Ratings Changes

OMER has been the topic of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, April 9th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.